在BCS期间接受IOERT作为增强剂的癌症乳腺癌患者的长期结果:一项单机构回顾性分析

Ulusal cerrahi dergisi Pub Date : 2023-06-19 eCollection Date: 2023-06-01 DOI:10.47717/turkjsurg.2023.5978
Semra Günay, Berk Gökçek, Özge Kandemir, Arzu Akan, Orhan Yalçın
{"title":"在BCS期间接受IOERT作为增强剂的癌症乳腺癌患者的长期结果:一项单机构回顾性分析","authors":"Semra Günay, Berk Gökçek, Özge Kandemir, Arzu Akan, Orhan Yalçın","doi":"10.47717/turkjsurg.2023.5978","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Intraoperative electron radiotherapy (IOERT) applied as boost to the tumor bed during breast conserving surgery is advantageous in terms of local recurrence in breast cancer patients. In addition, it has other advantages over the adjuvant boost RT such as no risk of tumor bed change, ease of sequencing radiotherapy chemotherapy, and reduced workload of the radiotherapy clinic. This study aimed to evaluate the long-term results of our patients who were treated with this method in our institution and are still being followed up.</p><p><strong>Material and methods: </strong>One hundred and three patients enrolled in this study received IOERT equivalent to 10 Gy as boost during BCS and were subsequently given adjuvant WBI according to the biological subtype of the tumor systemic therapy. These patients were analyzed using their files and hospital records. Patients were evaluated for overall survival, local recurrence, distant metastasis, and cosmetic outcome (using LENT-SOMA scale).</p><p><strong>Results: </strong>Median age was 53,5 (27-74), mean follow-up time was 75 (48-106) months. Mean pathological tumor size was 18 mm (4-30), 90 of the patients had invasive ductal carcinoma, eight of them were lobular and five of them had mixed histological structure. Ninety-three of the patients presented histological grade II, 15 grade III; 74 patients were luminal A-like, 15 luminal B-like, eight HER2 positive and six triple negative breast cancer. According to the LENT-SOMA scale, 35 had grade 0, 42 each had grade I, 23 had grade II, and two had grade III. All patients underwent whole breast irradiation after surgery, 81 received chemotherapy and 90 endocrine therapy. There was one local recurrence, distant recurrence was seen in four patients and one patient died of non-breast cancer causes. Overall survival was %99, and event free survival %96.</p><p><strong>Conclusion: </strong>IOERT for breast cancer treatment during BCS is a safe option with low chronic toxicity and the cosmetic outcome gets better over time.</p>","PeriodicalId":90992,"journal":{"name":"Ulusal cerrahi dergisi","volume":" ","pages":"115-120"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681109/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-term results of breast cancer patients who received IOERT as boost during BCS: A single-institution retrospective analysis.\",\"authors\":\"Semra Günay, Berk Gökçek, Özge Kandemir, Arzu Akan, Orhan Yalçın\",\"doi\":\"10.47717/turkjsurg.2023.5978\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Intraoperative electron radiotherapy (IOERT) applied as boost to the tumor bed during breast conserving surgery is advantageous in terms of local recurrence in breast cancer patients. In addition, it has other advantages over the adjuvant boost RT such as no risk of tumor bed change, ease of sequencing radiotherapy chemotherapy, and reduced workload of the radiotherapy clinic. This study aimed to evaluate the long-term results of our patients who were treated with this method in our institution and are still being followed up.</p><p><strong>Material and methods: </strong>One hundred and three patients enrolled in this study received IOERT equivalent to 10 Gy as boost during BCS and were subsequently given adjuvant WBI according to the biological subtype of the tumor systemic therapy. These patients were analyzed using their files and hospital records. Patients were evaluated for overall survival, local recurrence, distant metastasis, and cosmetic outcome (using LENT-SOMA scale).</p><p><strong>Results: </strong>Median age was 53,5 (27-74), mean follow-up time was 75 (48-106) months. Mean pathological tumor size was 18 mm (4-30), 90 of the patients had invasive ductal carcinoma, eight of them were lobular and five of them had mixed histological structure. Ninety-three of the patients presented histological grade II, 15 grade III; 74 patients were luminal A-like, 15 luminal B-like, eight HER2 positive and six triple negative breast cancer. According to the LENT-SOMA scale, 35 had grade 0, 42 each had grade I, 23 had grade II, and two had grade III. All patients underwent whole breast irradiation after surgery, 81 received chemotherapy and 90 endocrine therapy. There was one local recurrence, distant recurrence was seen in four patients and one patient died of non-breast cancer causes. Overall survival was %99, and event free survival %96.</p><p><strong>Conclusion: </strong>IOERT for breast cancer treatment during BCS is a safe option with low chronic toxicity and the cosmetic outcome gets better over time.</p>\",\"PeriodicalId\":90992,\"journal\":{\"name\":\"Ulusal cerrahi dergisi\",\"volume\":\" \",\"pages\":\"115-120\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681109/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ulusal cerrahi dergisi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47717/turkjsurg.2023.5978\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ulusal cerrahi dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47717/turkjsurg.2023.5978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:保乳手术中应用术中电子放疗(IOERT)助推肿瘤床有利于乳腺癌患者局部复发。此外,与辅助强化放疗相比,无肿瘤换床风险、放疗化疗排序简便、放疗临床工作量减少等优点。本研究旨在评估在我院使用该方法治疗并仍在随访的患者的长期效果。材料和方法:本研究纳入的103例患者在BCS期间接受相当于10 Gy的IOERT作为增强,随后根据肿瘤全身治疗的生物学亚型给予辅助WBI。这些患者通过他们的档案和医院记录进行分析。评估患者的总生存、局部复发、远处转移和美容结果(使用LENT-SOMA量表)。结果:中位年龄53,5(27-74),平均随访时间75(48-106)个月。病理肿瘤平均大小为18 mm(4 ~ 30), 90例为浸润性导管癌,8例为小叶癌,5例为混合性组织结构。组织学ⅱ级93例,ⅲ级15例;腔内a样74例,腔内b样15例,HER2阳性8例,三阴性6例。根据LENT-SOMA量表,0级35例,I级42例,II级23例,III级2例。所有患者术后均行全乳照射,化疗81例,内分泌治疗90例。1例局部复发,4例远处复发,1例非乳腺癌死亡。总生存率为%99,无事件生存率为%96。结论:IOERT治疗乳腺癌BCS是一种安全的选择,慢性毒性低,随着时间的推移,美容效果越来越好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term results of breast cancer patients who received IOERT as boost during BCS: A single-institution retrospective analysis.

Objectives: Intraoperative electron radiotherapy (IOERT) applied as boost to the tumor bed during breast conserving surgery is advantageous in terms of local recurrence in breast cancer patients. In addition, it has other advantages over the adjuvant boost RT such as no risk of tumor bed change, ease of sequencing radiotherapy chemotherapy, and reduced workload of the radiotherapy clinic. This study aimed to evaluate the long-term results of our patients who were treated with this method in our institution and are still being followed up.

Material and methods: One hundred and three patients enrolled in this study received IOERT equivalent to 10 Gy as boost during BCS and were subsequently given adjuvant WBI according to the biological subtype of the tumor systemic therapy. These patients were analyzed using their files and hospital records. Patients were evaluated for overall survival, local recurrence, distant metastasis, and cosmetic outcome (using LENT-SOMA scale).

Results: Median age was 53,5 (27-74), mean follow-up time was 75 (48-106) months. Mean pathological tumor size was 18 mm (4-30), 90 of the patients had invasive ductal carcinoma, eight of them were lobular and five of them had mixed histological structure. Ninety-three of the patients presented histological grade II, 15 grade III; 74 patients were luminal A-like, 15 luminal B-like, eight HER2 positive and six triple negative breast cancer. According to the LENT-SOMA scale, 35 had grade 0, 42 each had grade I, 23 had grade II, and two had grade III. All patients underwent whole breast irradiation after surgery, 81 received chemotherapy and 90 endocrine therapy. There was one local recurrence, distant recurrence was seen in four patients and one patient died of non-breast cancer causes. Overall survival was %99, and event free survival %96.

Conclusion: IOERT for breast cancer treatment during BCS is a safe option with low chronic toxicity and the cosmetic outcome gets better over time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信